| Document Date: 2013-12-17 08:54:34
Open Document File Size: 682,28 KBShare Result on Facebook
Company Gilead Sciences Inc. / HIV / / Event FDA Phase / Reorganization / / IndustryTerm hepatitis B therapy / healthcare / food / Treatment of HIV / / MedicalCondition DF / Fanconi syndrome / syphilis / headache / HBV / liver failure / dysfunction / acute viral infection / nausea / skin rash / hepatitis B / Arthralgias / fatigue / injury / Obesity / diarrhea / liver disease / renal dysfunction / infections / Immune reconstitution syndrome / abdominal pain / Autoimmune disorders / insomnia / negative infection / pneumonia / opportunistic infections / disease / hypophosphatemia / Carcinogenesis / acute HIV infection / POST-TREATMENT ACUTE EXACERBATION OF HEPATITIS B / fever / LACTIC ACIDOSIS / pancreatitis / osteomalacia / osteoporosis / infection / dizziness / depression / gonorrhea / rash / chronic hepatitis B / acute renal failure / syndrome / inflammatory / polymyositis / tuberculosis / / MedicalTreatment antiretroviral treatment / antiretroviral therapy / vaccination / hemodialysis / renal replacement therapy / / Organization FDA / / / Position counsel / / Product Combivir / EMTRIVA / zidovudine / Trizivir / abacavir sulfate / TRUVADA / Vitamin D / HEPSERA / Epivir / Epzicom / Epivir-HBV / tenofovir disoproxil fumarate / lamivudine / VIREAD / Didanosine / ATRIPLA / HEPSERA® / HIV-1 / / Technology antibodies / Pharmacokinetics / / URL www.fda.gov/medwatch / /
SocialTag |
CrCl is below 60 mL/min. If a decrease in CrCl is observed in uninfected individuals while using TRUVADA for PrEP, evaluate potential causes and re-assess potential risks and benefits of continued use[removed]HIGHLIGHTS